Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Neutral 61.8%

Neg 0% Neu 61.8% Pos 0%

Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.